Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S. Quartuccio L, et al. Among authors: saracco m. Rheumatology (Oxford). 2009 Dec;48(12):1557-9. doi: 10.1093/rheumatology/kep314. Epub 2009 Sep 29. Rheumatology (Oxford). 2009. PMID: 19789202
[Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
Quartuccio L, Salvin S, Saracco M, Lombardi S, Fabris M, Mansutti E, Maset M, Pellerito S, De Vita S. Quartuccio L, et al. Among authors: saracco m. Reumatismo. 2009 Jul-Sep;61(3):182-6. doi: 10.4081/reumatismo.2009.182. Reumatismo. 2009. PMID: 19888503 Free article. Italian.
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis.
Fabris M, Quartuccio L, Lombardi S, Saracco M, Atzeni F, Carletto A, Cimmino M, Fabro C, Pontarini E, Pellerito R, Bambara LM, Sarzi-Puttini P, Cutolo M, Manfredi M, Benucci M, Morassi P, Fischetti F, Padovan M, Govoni M, Curcio F, Tonutti E, De Vita S. Fabris M, et al. Among authors: saracco m. Autoimmun Rev. 2012 Mar;11(5):315-20. doi: 10.1016/j.autrev.2010.06.012. Epub 2010 Oct 23. Autoimmun Rev. 2012. PMID: 20974296
Iloprost modulates the immune response in systemic sclerosis.
D'Amelio P, Cristofaro MA, D'Amico L, Veneziano L, Roato I, Sassi F, Bisignano G, Saracco M, Pellerito R, Patanè S, Ferracini R, Pescarmona GP, Isaia GC. D'Amelio P, et al. Among authors: saracco m. BMC Immunol. 2010 Dec 15;11:62. doi: 10.1186/1471-2172-11-62. BMC Immunol. 2010. PMID: 21159177 Free PMC article. Clinical Trial.
Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.
Fabris M, Quartuccio L, Lombardi S, Benucci M, Manfredi M, Saracco M, Atzeni F, Morassi P, Cimmino MA, Pontarini E, Fabro C, Pellerito R, Sarzi-Puttini P, Cutolo M, Carletto A, Bambara LM, Fischetti F, Curcio F, Tonutti E, De Vita S. Fabris M, et al. Among authors: saracco m. Reumatismo. 2010 Oct-Dec;62(4):253-8. doi: 10.4081/reumatismo.2010.253. Reumatismo. 2010. PMID: 21253618 Free article.
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S. Fabris M, et al. Among authors: saracco m. Arthritis Rheum. 2013 Jan;65(1):88-97. doi: 10.1002/art.37707. Arthritis Rheum. 2013. PMID: 23001900 Free article.
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S. Quartuccio L, et al. Among authors: saracco m. Ann Rheum Dis. 2014 Apr;73(4):716-21. doi: 10.1136/annrheumdis-2012-202435. Epub 2013 Mar 16. Ann Rheum Dis. 2014. PMID: 23505228
Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: A multi-centric study.
Ariani A, Silva M, Bravi E, Saracco M, Parisi S, De Gennaro F, Lumetti F, Idolazzi L, Seletti V, Caramaschi P, Benini C, Bodini FC, Scirè CA, Lucchini G, Santilli D, Mozzani F, Imberti D, Arrigoni E, Delsante G, Pellerito R, Fusaro E, Sverzellati N. Ariani A, et al. Among authors: saracco m. Mod Rheumatol. 2015 Sep;25(5):724-30. doi: 10.3109/14397595.2015.1016200. Epub 2015 May 5. Mod Rheumatol. 2015. PMID: 25736361
Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis.
Ariani A, Silva M, Seletti V, Bravi E, Saracco M, Parisi S, De Gennaro F, Idolazzi L, Caramaschi P, Benini C, Bodini FC, Scirè CA, Carrara G, Lumetti F, Alfieri V, Bonati E, Lucchini G, Aiello M, Santilli D, Mozzani F, Imberti D, Michieletti E, Arrigoni E, Delsante G, Pellerito R, Fusaro E, Chetta A, Sverzellati N. Ariani A, et al. Among authors: saracco m. Rheumatology (Oxford). 2017 Jun 1;56(6):922-927. doi: 10.1093/rheumatology/kew480. Rheumatology (Oxford). 2017. PMID: 28160007
93 results